Prostate Cancer Clinical Trial
Official title:
A Comparative Study of CO2 Exchange Patterns Between Valve-free Trocar (AirSeal®) Versus Standard Trocar (Endopath®) During Robotic Prostatectomies
NCT number | NCT02114164 |
Other study ID # | OH1-13-00489 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2016 |
Est. completion date | July 15, 2019 |
Verified date | October 2021 |
Source | OhioHealth |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.
Status | Completed |
Enrollment | 109 |
Est. completion date | July 15, 2019 |
Est. primary completion date | May 3, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age>18 - Eligible and elect to undergo robotic prostatectomy surgery @ OhioHealth Dublin Methodist Hospital Exclusion Criteria: - Age < 18 - Emergency surgery - Ascites - BMI>44 or <18 |
Country | Name | City | State |
---|---|---|---|
United States | Dublin Methodist Hospital | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
OhioHealth | SurgiQuest, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraoperative Pneumoperitoneal Pressure (mmHg) | Pneumoperitoneal pressure is the pressure exerted by air or gas in the abdominal (peritoneal) cavity. As the amount of air/gas increases, the pressure (mmHg) increases. The highest pressure that occurred during the procedure was compared between groups. | Through end of procedure, an average of 156 minutes | |
Secondary | Intraoperative Arterial Blood Gas Carbon Dioxide (mmHg). | The amount of dissolved carbon dioxide (PaCO2) in arterial blood (mmHg) during the operative procedure | Baseline, 60 minutes, and at end of procedure, an average of 156 minutes | |
Secondary | End-tidal Carbon Dioxide Pressure (mmHg) | End-tidal carbon dioxide pressure is the partial pressure of carbon dioxide at the end of exhalation. Normal value is 35-45 mmHg. | Baseline, 60 minutes, and at end of procedure, an average of 156 minutes | |
Secondary | Carbon Dioxide Elimination (mmHg) | Carbon dioxide elimination was calculated using end-tidal carbon dioxide pressure (EtCO2), tidal volume, respiratory rate, barometric pressure (pB = 760mm Hg), partial pressure of water vapor (PH2O = 13 mm Hg), and patient weight (kg) | Baseline, 60 minutes, and at end of procedure, an average of 156 minutes | |
Secondary | Intraoperative Arterial Blood Gas Oxygen (mmHg). | The amount of dissolved oxygen (PaO2) in arterial blood (mmHg). | Baseline, 60 minutes, and end of procedure, an average of 156 minutes | |
Secondary | Number of Ventilator Interventions | The number of times the anesthesiologist had to adjust ventilator settings | Through end of procedure, an average of 156 minutes | |
Secondary | Procedure Time (Minutes) | The duration of the procedure | Through end of procedure, an average of 156 minutes | |
Secondary | Smoke Evacuation Quality | Smoke evacuation quality throughout the procedure was assessed by the surgeon as below average, average, or above average | Through end of procedure, an average of 156 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |